We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Dynavax Reports Phase 1B Safety and Immunogenicity Results for Hepatitis B Therapy Candidate
News

Dynavax Reports Phase 1B Safety and Immunogenicity Results for Hepatitis B Therapy Candidate

Dynavax Reports Phase 1B Safety and Immunogenicity Results for Hepatitis B Therapy Candidate
News

Dynavax Reports Phase 1B Safety and Immunogenicity Results for Hepatitis B Therapy Candidate

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Dynavax Reports Phase 1B Safety and Immunogenicity Results for Hepatitis B Therapy Candidate"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The dose escalation study assessed safety and the immunologic and virologic responses in 14 subjects with chronic hepatitis B infection. The Phase 1b data showed:

•    All doses were generally safe and well tolerated; and
•    Individual immunologic and virologic responses were observed across cohorts at all dose levels.

No conclusions regarding the potential clinical impact of the therapy could be reached in this small study. Dynavax's treatment approach combines both the surface and core hepatitis B virus (HBV) antigens with ISCOMATRIX® adjuvant originally entered into development by Rhein Biotech prior to its acquisition by Dynavax in 2006. The candidate vaccine, DV-601, is designed to induce an immune response against HBV-infected cells and if proven to be safe and effective, may offer an alternative therapeutic option for patients chronically infected with HBV.

Advertisement